Big Pharma’s Academic Courtship Continues With Pfizer-UCSF, Glaxo-IDI Research Pacts | GenomeWeb
A pair of pharma giants inked broad research and drug-discovery collaborations with prominent US research institutions this month, continuing the recent trend of pharmaceutical companies dipping into academic waters to replenish their drug pipelines. 
 
The deals, between GlaxoSmithKline and the Immune Disease Institute, and between Pfizer and the University of California, San Francisco, are similar in their overarching goals but differ in scope.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.